Please login to the form below

Not currently logged in
Email:
Password:

Astex in $500m deal

Astex Therapeutics has signed a new research deal with Janssen Pharmaceutica, which could see the company earn close to $500m in royalty payments
Astex Therapeutics has signed a new research deal with Janssen Pharmaceutica, which could see the company earn close to $500m in royalty payments.

The agreement effectively grants Janssen Pharmaceutica, a US company owned by Johnson & Johnson, exclusive rights to develop compounds from Astex's fibroblast growth factor receptor (FGFR) inhibitor programme. Responsibility for clinical and pre-clinical R&D of the compounds will fall to Ortho Biotech Research & Development, a division of Janssen Pharmaceutica.

Astex now stands to receive $37.4m in upfront cash, equity payments, and research funding over a two-year period. The deal signals the creation of a novel drug discovery programme that is focused on developing treatments for cancer, with two specific research targets having already been set.

"This is another landmark agreement for Astex," said Harren Jhoti, CEO of Astex Therapeutics.

"This partnership is another testament to Astex's position as the leader in fragment-based drug discovery and the productivity generated by our platform."

The company says that these latest developments serve as proof of the efficacy of its proprietary drug discovery platform, Pyramid, which has generated one new cancer drug candidate for clinical testing per year since 2004.

Under the terms of the deal, Astex now has the right to commercialise FGFR products developed under the US collaboration.

9th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics